Khang & Khang LLP (the "Firm") announces that it is investigating claims against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR) concerning possible violations of federal securities laws.

If you purchased shares of CytRx and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the July 12, 2016 disclosure of the results of the Company's Phase 3 clinical trial of aldoxorubicin, which did not show any improvement from other commonly used cancer drugs. CytRx stated that almost half of the patients in the Phase 3 trial were excluded from the data since the study was disturbed by a partial clinical hold on November 2014. When this news was announced, stock prices fell sharply.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on

Copyright Business Wire 2010